ABSTRACT
Nicorandil, opener of potassium channels, was studied in Russia and abroad. Its cardioprotective, anti-ischemic, pharmacokinetic and pharmacodynamic properties are reviewed as well as side effects and area of application in patients with stable coronary heart disease (CHD). The trial have found efficacy of nicorandil in prevention of anginal attacks. Also, the drug increases exercise tolerance. Administration of nicorandil is indicated before intervention on coronary arteries for reproduction of the effect of myocardial preconditioning. Nicorandil is recommended for treatment of patients with chronic stable coronary heart disease.
Subject(s)
Cardiotonic Agents , Coronary Disease/drug therapy , Nicorandil , Administration, Oral , Biological Availability , Cardiotonic Agents/pharmacokinetics , Cardiotonic Agents/pharmacology , Cardiotonic Agents/therapeutic use , Clinical Trials as Topic , Humans , Nicorandil/pharmacokinetics , Nicorandil/pharmacology , Nicorandil/therapeutic use , Treatment OutcomeABSTRACT
The therapeutic efficiency of bioactive preparations of the liver and spleen in the treatment of experimental toxic cirrhosis of the liver is shown. Evaluation of the nucleolar organizer activity showed the highest efficiency of treatment with human fetal liver extract.
Subject(s)
Hepatitis, Chronic/drug therapy , Hepatocytes/cytology , Liver Cirrhosis/drug therapy , Liver Extracts/therapeutic use , Nucleolus Organizer Region/drug effects , Nucleolus Organizer Region/metabolism , Spleen/chemistry , Animals , Hepatocytes/metabolism , Liver Extracts/pharmacology , Rats , Silver StainingABSTRACT
Prophylactic efficacy of remantadin was studied during influenza epidemics caused by types A (H3N2) and B viruses. More than 15,000 persons were observed. Daily administration of remantadin ensured a decrease in influenza A (but not influenza B) morbidity 1.5-4.5 times in different groups (planned prophylaxis) and 6.5-10.3 times in family foci (focal prophylaxis). The protective effect of remantadin is mainly due to its capacity of suppressing the toxic manifestations of influenza infection, which is accompanied by a decrease in the frequency and duration of clinically pronounced disease and an increase in the proportion of asymptomatic forms.
Subject(s)
Adamantane/analogs & derivatives , Disease Outbreaks/prevention & control , Influenza, Human/prevention & control , Rimantadine/therapeutic use , Adolescent , Adult , Drug Evaluation , Female , Humans , Influenza Vaccines/administration & dosage , Male , Placebos , USSRSubject(s)
Amantadine/therapeutic use , Respiratory Tract Infections/drug therapy , Virus Diseases/drug therapy , Antibodies, Bacterial/analysis , Antibodies, Viral/analysis , Drug Evaluation , Humans , Mycoplasma pneumoniae/immunology , Pneumonia, Mycoplasma/drug therapy , Pneumonia, Mycoplasma/immunology , Respiratory Tract Infections/immunology , Virus Diseases/immunologyABSTRACT
The results of double blind clinical, phisiological, biochemical immunological and virological studies carried out in 460 normal volunteers gave sufficiently objective evaluation of safety and antiinfluenza activity of bonaphthone. The new antiviral drug is recommended for wide epidemiological trials. In epidemiological, coded and strictly controlled experiment during influenza A/England epidemic in 1973 involving 1393 persons the prophylactic effectiveness of bonaphthone was established (the index of effectiveness 2.09).